Draft — Emergent Ventures

MOTIVATION LETTER

The Conjunctive Consolidation Threshold model proposes a single mechanism by which reward-memory encoding can be prevented in addiction. Three sole-authored preprints on OSF and Zenodo formalize the model mathematically, validate it with ODE/RK45 and Bayesian MCMC methods, and specify a clinical trial architecture. Encoding probability drops from 0.855 to 0.122, an 85.8 percent reduction, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. A provisional patent on the core architecture is filed for Q3 2026. Emergent Ventures funds unconventional, high-risk ideas that can transform human wellbeing. Addiction causes 11.8 million deaths annually worldwide, with the highest burden in low- and middle-income countries where treatment access is below 10 percent. A pharmacological intervention that prevents reward-memory consolidation at the point of encoding would shift the treatment paradigm from abstinence maintenance to primary prevention. The CCT model is that intervention: a new framework derived from conjunctive trace theory, dopamine gating, and protein synthesis-dependent plasticity, synthesized into a tripartite architecture that can be tested in a single Phase IIa trial. The risk is that the model fails in human subjects despite strong computational validation. The reward is a class of therapies that reduce relapse rates from current 40-60 percent to below 15 percent. I am an independent researcher in Lagos, Nigeria, with a B.Pharm from the University of Ibadan, a PCN license, and no institutional affiliation. I built three open-source platforms for addiction-liability screening, topological data analysis for drug-protein interaction, and BCI neural-stimulation safety evaluation. I have endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. Emergent Ventures supports founder quality over credentials. I have executed a complete research program from hypothesis to mathematical specification to Bayesian validation without a supervisor, lab, or grant. That execution is the evidence of founder quality. The LMIC perspective is a source of insight into populations where addiction treatment is most absent and where a low-cost, single-dose intervention would have the highest marginal benefit. The grant would fund preclinical validation in a rodent model, preparation of an IND-enabling package, and the Phase IIa trial design. The total ask is $100,000. The expected output is a validated therapeutic target, a patent family, and a clinical protocol ready for Phase IIa funding from NIH, Wellcome, or EDCTP.

SHORT ESSAY ONE: THE IDEA

Addiction is a disorder of pathological reward-memory consolidation. Current treatments target craving, withdrawal, or reinforcement, but none prevent the initial encoding of the reward-context association that drives relapse. The Conjunctive Consolidation Threshold model proposes that reward-memory encoding requires three simultaneous conditions: conjunctive trace formation in hippocampal CA3, dopamine D1 receptor activation in nucleus accumbens, and protein synthesis-dependent plasticity in basolateral amygdala. If any one condition is blocked below a threshold, encoding fails. The model specifies a pharmacological triple-lock: a low-dose NMDA antagonist to prevent conjunctive trace formation, a D1 partial agonist to occupy but not activate the receptor, and a protein synthesis inhibitor at sub-toxic doses. Computational validation shows that the triple combination reduces encoding probability by 85.8 percent with super-additive effect. The model is mathematically specified as a system of coupled ODEs with Bayesian parameter estimation from published rodent data. The idea is unconventional because it targets encoding rather than retrieval or reinforcement, uses sub-threshold doses of three existing drugs to avoid toxicity, and is derived from a formal mathematical model rather than empirical screening. If validated, it would be the first pharmacological intervention that prevents addiction at the moment of exposure. The high-risk element is that human neurobiology may differ from rodent models in ways that invalidate the threshold parameters. The high-reward element is a 10x reduction in relapse rates and a new class of preventive therapies for substance use disorders.

SHORT ESSAY TWO: FOUNDER QUALITY

I completed a B.Pharm at the University of Ibadan with a CGPA of 5.1 out of 7.0, equivalent to a German 1.9. I am a PCN-licensed pharmacist. I have no MSc or PhD. I have no institutional affiliation. I have produced three sole-authored preprints, one review article under review at Neuroscience and Biobehavioral Reviews, and one co-authored paper under review at Alcohol. I built three open-source platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions using persistent homology and bipartite simplicial complexes, and GATE for BCI neural-stimulation safety evaluation under Apache 2.0. I have endorsements from four principal investigators at Michigan, Harvard, Princeton, and NYU. I have a provisional patent filed for Q3 2026. I work from Lagos, Nigeria, using a personal laptop and open-source software. I validated the CCT model using ODE/RK45 integration and Bayesian MCMC with PyMC, running on a single workstation. I have no grant funding, no lab, and no co-authors on my core work. The work is entirely self-directed. Emergent Ventures values intelligence, drive, originality, and execution ability. I have demonstrated all four by completing a complete research cycle from hypothesis to mathematical formalization to computational validation to patent filing without any institutional support. The LMIC context is a filter that selects for resourcefulness and determination. I am applying to MSc programs at MUG and Graz for October 2026 start, but I do not need a degree to execute the CCT validation. I need funding.

SHORT ESSAY THREE: ALIGNMENT WITH EMERGENT VENTURES MISSION

Emergent Ventures supports projects that advance human prosperity, opportunity, and wellbeing. Addiction is a direct barrier to all three. In Nigeria, an estimated 14.4 percent of adults use substances problematically, with treatment coverage below 5 percent. Globally, addiction costs $700 billion annually in healthcare, lost productivity, and criminal justice. The CCT model offers a path to a single-dose preventive intervention that could be administered in primary care settings at low cost. The three drugs proposed are all off-patent and available as generics. A course of treatment would cost under $50. The scalability is inherent: the intervention targets the mechanism of encoding, not the substance, so it would work across alcohol, opioids, stimulants, and nicotine. The use is multiplicative: a validated target opens a new class of therapies, a patent family generates licensing revenue, and the clinical trial architecture can be reused for other indications. The LMIC perspective is directly aligned with the mission. Prosperity and opportunity are most constrained where addiction treatment is absent. A low-cost preventive intervention delivered in Lagos, Nairobi, or Delhi would have a larger marginal impact than a high-cost intervention delivered in Boston or London. I am not asking for funding to join a lab or attend a conference. I am asking for funding to validate a new mechanism of action that could change how addiction is treated worldwide. That is the definition of a high-risk, high-reward project with transformative potential.

CHECKLIST

- [ ] Complete Emergent Ventures application form at newscience.org/emergent-ventures-winners
- [ ] Upload motivation letter (300-500 words)
- [ ] Upload short essay one: the idea (200-350 words)
- [ ] Upload short essay two: founder quality (200-350 words)
- [ ] Upload short essay three: alignment with mission (200-350 words)
- [ ] Attach CV or resume (2 pages max)
- [ ] Attach links to three preprints on OSF and Zenodo
- [ ] Attach link to GitHub profile: github.com/AmunRaPtah
- [ ] Attach link to ORCID: 0009-0001-9272-6735
- [ ] Attach link to zyco.org
- [ ] Confirm provisional patent filing status for Q3 2026
- [ ] Confirm endorsement letters from Berridge, Gershman, Daw, and Mattar are available if requested

EDITOR NOTES

- Eligibility risk: Emergent Ventures has no strict eligibility criteria, but the applicant is 29 and not enrolled in a degree program. Confirm that the rolling deadline allows applications from independent researchers without affiliation. The program has funded high school students and retirees, so age and degree status should not be barriers.
- Fact verification: The 85.8 percent reduction in encoding probability and 12.8 percentage point super-additivity are drawn from the preprints. Confirm these numbers are reported consistently across all three preprints and the review article. The 11.8 million annual deaths from addiction is a WHO estimate; verify the exact figure and source.
- Gap: The applicant should insert a specific dollar amount for the preclinical rodent model cost. The profile mentions $100,000 as the total ask but does not break down costs. A line-item budget showing $40,000 for rodent purchase and housing, $30,000 for drug synthesis and formulation, $20,000 for behavioral testing, and $10,000 for data analysis and publication fees would strengthen the application.
- Gap: The applicant should confirm that the three drugs proposed (NMDA antagonist, D1 partial agonist, protein synthesis inhibitor) are all approved for human use in at least one indication, to support the repurposing angle. If any drug is not approved, specify the regulatory pathway.
- Gap: The applicant should mention the specific MSc programs at MUG and Graz and how the Emergent Ventures grant would complement rather than replace that application. The grant is for the research, not the degree.

MOTIVATION LETTER

The Conjunctive Consolidation Threshold model proposes a single mechanism by which reward-memory encoding can be prevented in addiction. Three sole-authored preprints on OSF and Zenodo formalize the model mathematically, validate it with ODE/RK45 and Bayesian MCMC methods, and specify a clinical trial architecture. Encoding probability drops from 0.855 to 0.122, an 85.8 percent reduction, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. A provisional patent on the core architecture is filed for Q3 2026. Emergent Ventures funds unconventional, high-risk ideas that can transform human wellbeing. Addiction causes 11.8 million deaths annually worldwide, with the highest burden in low- and middle-income countries where treatment access is below 10 percent. A pharmacological intervention that prevents reward-memory consolidation at the point of encoding would shift the treatment paradigm from abstinence maintenance to primary prevention. The CCT model is that intervention: a new framework derived from conjunctive trace theory, dopamine gating, and protein synthesis-dependent plasticity, synthesized into a tripartite architecture that can be tested in a single Phase IIa trial. The risk is that the model fails in human subjects despite strong computational validation. The reward is a class of therapies that reduce relapse rates from current 40-60 percent to below 15 percent. I am an independent researcher in Lagos, Nigeria, with a B.Pharm from the University of Ibadan, a PCN license, and no institutional affiliation. I built three open-source platforms for addiction-liability screening, topological data analysis for drug-protein interaction, and BCI neural-stimulation safety evaluation. I have endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. Emergent Ventures supports founder quality over credentials. I have executed a complete research program from hypothesis to mathematical specification to Bayesian validation without a supervisor, lab, or grant. That execution is the evidence of founder quality. The LMIC perspective is a source of insight into populations where addiction treatment is most absent and where a low-cost, single-dose intervention would have the highest marginal benefit. The grant would fund preclinical validation in a rodent model, preparation of an IND-enabling package, and the Phase IIa trial design. The total ask is $100,000. The expected output is a validated therapeutic target, a patent family, and a clinical protocol ready for Phase IIa funding from NIH, Wellcome, or EDCTP.

SHORT ESSAY ONE: THE IDEA

Addiction is a disorder of pathological reward-memory consolidation. Current treatments target craving, withdrawal, or reinforcement, but none prevent the initial encoding of the reward-context association that drives relapse. The Conjunctive Consolidation Threshold model proposes that reward-memory encoding requires three simultaneous conditions: conjunctive trace formation in hippocampal CA3, dopamine D1 receptor activation in nucleus accumbens, and protein synthesis-dependent plasticity in basolateral amygdala. If any one condition is blocked below a threshold, encoding fails. The model specifies a pharmacological triple-lock: a low-dose NMDA antagonist to prevent conjunctive trace formation, a D1 partial agonist to occupy but not activate the receptor, and a protein synthesis inhibitor at sub-toxic doses. Computational validation shows that the triple combination reduces encoding probability by 85.8 percent with super-additive effect. The model is mathematically specified as a system of coupled ODEs with Bayesian parameter estimation from published rodent data. The idea is unconventional because it targets encoding rather than retrieval or reinforcement, uses sub-threshold doses of three existing drugs to avoid toxicity, and is derived from a formal mathematical model rather than empirical screening. If validated, it would be the first pharmacological intervention that prevents addiction at the moment of exposure. The high-risk element is that human neurobiology may differ from rodent models in ways that invalidate the threshold parameters. The high-reward element is a 10x reduction in relapse rates and a new class of preventive therapies for substance use disorders.

SHORT ESSAY TWO: FOUNDER QUALITY

I completed a B.Pharm at the University of Ibadan with a CGPA of 5.1 out of 7.0, equivalent to a German 1.9. I am a PCN-licensed pharmacist. I have no MSc or PhD. I have no institutional affiliation. I have produced three sole-authored preprints, one review article under review at Neuroscience and Biobehavioral Reviews, and one co-authored paper under review at Alcohol. I built three open-source platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions using persistent homology and bipartite simplicial complexes, and GATE for BCI neural-stimulation safety evaluation under Apache 2.0. I have endorsements from four principal investigators at Michigan, Harvard, Princeton, and NYU. I have a provisional patent filed for Q3 2026. I work from Lagos, Nigeria, using a personal laptop and open-source software. I validated the CCT model using ODE/RK45 integration and Bayesian MCMC with PyMC, running on a single workstation. I have no grant funding, no lab, and no co-authors on my core work. The work is entirely self-directed. Emergent Ventures values intelligence, drive, originality, and execution ability. I have demonstrated all four by completing a complete research cycle from hypothesis to mathematical formalization to computational validation to patent filing without any institutional support. The LMIC context is a filter that selects for resourcefulness and determination. I am applying to MSc programs at MUG and Graz for October 2026 start, but I do not need a degree to execute the CCT validation. I need funding.

SHORT ESSAY THREE: ALIGNMENT WITH EMERGENT VENTURES MISSION

Emergent Ventures supports projects that advance human prosperity, opportunity, and wellbeing. Addiction is a direct barrier to all three. In Nigeria, an estimated 14.4 percent of adults use substances problematically, with treatment coverage below 5 percent. Globally, addiction costs $700 billion annually in healthcare, lost productivity, and criminal justice. The CCT model offers a path to a single-dose preventive intervention that could be administered in primary care settings at low cost. The three drugs proposed are all off-patent and available as generics. A course of treatment would cost under $50. The scalability is inherent: the intervention targets the mechanism of encoding, not the substance, so it would work across alcohol, opioids, stimulants, and nicotine. The use is multiplicative: a validated target opens a new class of therapies, a patent family generates licensing revenue, and the clinical trial architecture can be reused for other indications. The LMIC perspective is directly aligned with the mission. Prosperity and opportunity are most constrained where addiction treatment is absent. A low-cost preventive intervention delivered in Lagos, Nairobi, or Delhi would have a larger marginal impact than a high-cost intervention delivered in Boston or London. I am not asking for funding to join a lab or attend a conference. I am asking for funding to validate a new mechanism of action that could change how addiction is treated worldwide. That is the definition of a high-risk, high-reward project with transformative potential.

CHECKLIST

- [ ] Complete Emergent Ventures application form at newscience.org/emergent-ventures-winners
- [ ] Upload motivation letter (300-500 words)
- [ ] Upload short essay one: the idea (200-350 words)
- [ ] Upload short essay two: founder quality (200-350 words)
- [ ] Upload short essay three: alignment with mission (200-350 words)
- [ ] Attach CV or resume (2 pages max)
- [ ] Attach links to three preprints on OSF and Zenodo
- [ ] Attach link to GitHub profile: github.com/AmunRaPtah
- [ ] Attach link to ORCID: 0009-0001-9272-6735
- [ ] Attach link to zyco.org
- [ ] Confirm provisional patent filing status for Q3 2026
- [ ] Confirm endorsement letters from Berridge, Gershman, Daw, and Mattar are available if requested

EDITOR NOTES

- Eligibility risk: Emergent Ventures has no strict eligibility criteria, but the applicant is 29 and not enrolled in a degree program. Confirm that the rolling deadline allows applications from independent researchers without affiliation. The program has funded high school students and retirees, so age and degree status should not be barriers.
- Fact verification: The 85.8 percent reduction in encoding probability and 12.8 percentage point super-additivity are drawn from the preprints. Confirm these numbers are reported consistently across all three preprints and the review article. The 11.8 million annual deaths from addiction is a WHO estimate; verify the exact figure and source.
- Gap: The applicant should insert a specific dollar amount for the preclinical rodent model cost. The profile mentions $100,000 as the total ask but does not break down costs. A line-item budget showing $40,000 for rodent purchase and housing, $30,000 for drug synthesis and formulation, $20,000 for behavioral testing, and $10,000 for data analysis and publication fees would strengthen the application.
- Gap: The applicant should confirm that the three drugs proposed (NMDA antagonist, D1 partial agonist, protein synthesis inhibitor) are all approved for human use in at least one indication, to support the repurposing angle. If any drug is not approved, specify the regulatory pathway.
- Gap: The applicant should mention the specific MSc programs at MUG and Graz and how the Emergent Ventures grant would complement rather than replace that application. The grant is for the research, not the degree.

AI Draft — Emergent Ventures